Background Healthcare-utilization data for multiple sclerosis (MS) are scarce in Germany.
The Purpose of the study was to analyse administrative prevalence of MS, medication use …

Background: Multiple sclerosis (MS) quality of care guidelines are consensus-based. The
effectiveness of the recommendations is unknown. Objective: To determine whether clinic …

The mechanisms leading to disability and the long-term efficacy and safety of disease
modifying drugs (DMDs) in multiple sclerosis (MS) are unclear. We aimed at building a …

Multiple sclerosis (MS) is a chronic progressive disease of the CNS causing disability and
neurological symptoms that carry a substantial burden. Previous Italian studies appear …

Background and purpose Disease‐modifying therapies (DMTs) have an impact on relapses
and disease progression. Nonetheless, many patients with multiple sclerosis (MS) remain …

Multiple sclerosis (MS) is uncommon in China and the standard of care is underdeveloped,
with limited utilization of disease-modifying treatment (DMT). An understanding of real-world …

Objective: To identify evidence in the literature presenting the economic and humanistic
(based on health state utility values [HSUVs]) burden of multiple sclerosis (MS) and report …

Background Cost-of-illness (COI) studies of Multiple Sclerosis (MS) are vital components for
describing the economic burden of MS, and are frequently used in model studies of …

BACKGROUND: Multiple sclerosis (MS) is the most common neurological disease among
young adults in Canada, but few studies to date have measured the burden imposed by MS …

The “MS in the 21st Century” initiative was established with the purpose of (1) defining how
multiple sclerosis (MS) treatment and standards of care should look in the 21st century;(2) …